Literature DB >> 8319729

Liver transplantation for type I and type IV glycogen storage disease.

R Selby1, T E Starzl, E Yunis, S Todo, A G Tzakis, B I Brown, R S Kendall.   

Abstract

Progressive liver failure or hepatic complications of the primary disease led to orthotopic liver transplantation in eight children with glycogen storage disease over a 9-year period. One patient had glycogen storage disease (GSD) type I (von Gierke disease) and seven patients had type IV GSD (Andersen disease). As previously reported [19], a 16.5-year-old-girl with GSD type I was successfully treated in 1982 by orthotopic liver transplantation under cyclosporine and steroid immunosuppression. The metabolic consequences of the disease have been eliminated, the renal function and size have remained normal, and the patient has lived a normal young adult life. A late portal venous thrombosis was treated successfully with a distal splenorenal shunt. Orthotopic liver transplantation was performed in seven children with type N GSD who had progressive hepatic failure. Two patients died early from technical complications. The other five have no evidence of recurrent hepatic amylopectinosis after 1.1-5.8 postoperative years. They have had good physical and intellectual maturation. Amylopectin was found in many extrahepatic tissues prior to surgery, but cardiopathy and skeletal myopathy have not developed after transplantation. Postoperative heart biopsies from patients showed either minimal amylopectin deposits as long as 4.5 years following transplantation or a dramatic reduction in sequential biopsies from one patient who initially had dense myocardial deposits. Serious hepatic derangement is seen most commonly in types I and IV GSD. Liver transplantation cures the hepatic manifestations of both types. The extrahepatic deposition of abnormal glycogen appears not to be problematic in type I disease, and while potentially more threatening in type IV disease, may actually exhibit signs of regression after hepatic allografting.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319729      PMCID: PMC2974302          DOI: 10.1007/bf02072093

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  31 in total

1.  Hepatotrophic effects of FK506 in dogs.

Authors:  T E Starzl; K A Porter; V Mazzaferro; S Todo; J Fung; A Francavilla
Journal:  Transplantation       Date:  1991-01       Impact factor: 4.939

2.  Glycogenosis. IV. A new cause of infantile hypotonia.

Authors:  H Zellweger; S Mueller; V Ionasescu; S S Schochet; W F McCormick
Journal:  J Pediatr       Date:  1972-05       Impact factor: 4.406

3.  Lack of an alpha-1,4-glucan: alpha-1,4-glucan 6-glycosyl transferase in a case of type IV glycogenosis.

Authors:  B I Brown; D H Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1966-08       Impact factor: 11.205

4.  Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, alpha 1-antitrypsin, C8, and factor B.

Authors:  C A Alper; D Raum; Z L Awdeh; B H Petersen; P D Taylor; T E Starzl
Journal:  Clin Immunol Immunopathol       Date:  1980-05

5.  Nervous system involvement in type IV glycogenosis.

Authors:  K R McMaster; J M Powers; G R Hennigar; H J Wohltmann; G H Farr
Journal:  Arch Pathol Lab Med       Date:  1979-03       Impact factor: 5.534

6.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

7.  Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs.

Authors:  T E Starzl; K Watanabe; K A Porter; C W Putnam
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

8.  Structure of glycogens and amylopectins. III. Normal and abnormal human glycogen.

Authors:  B ILLINGWORTH; G T CORI
Journal:  J Biol Chem       Date:  1952-12       Impact factor: 5.157

9.  Human C'3: evidence for the liver as the primary site of synthesis.

Authors:  C A Alper; A M Johnson; A G Birtch; F D Moore
Journal:  Science       Date:  1969-01-17       Impact factor: 47.728

10.  Type IV glycogenosis (amylopectinosis). Light and electron microscopic observations.

Authors:  S S Schochet; W F McCormick; H Zellweger
Journal:  Arch Pathol       Date:  1970-10
View more
  8 in total

1.  Living Donor Liver Transplantation in a Korean Child with Glycogen Storage Disease Type IV and a GBE1 Mutation.

Authors:  Hye Ryun Ban; Kyung Mo Kim; Joo Young Jang; Gu-Hwan Kim; Han-Wook You; Kyungeun Kim; Eunsil Yu; Dae Yeon Kim; Ki Hun Kim; Young Joo Lee; Sung Gyu Lee; Young Nyun Park; Hong Koh; Ki Sup Chung
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

Review 2.  Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management.

Authors:  Kimihiko Oishi; Ronen Arnon; Melissa P Wasserstein; George A Diaz
Journal:  Pediatr Transplant       Date:  2016-06-21

3.  Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia.

Authors:  L Faivre; D Houssin; J Valayer; J Brouard; M Hadchouel; O Bernard
Journal:  J Inherit Metab Dis       Date:  1999-08       Impact factor: 4.982

Review 4.  Liver transplantation for glycogen storage disease types I, III, and IV.

Authors:  D Matern; T E Starzl; W Arnaout; J Barnard; J S Bynon; A Dhawan; J Emond; E B Haagsma; G Hug; A Lachaux; G P Smit; Y T Chen
Journal:  Eur J Pediatr       Date:  1999-12       Impact factor: 3.183

5.  The potential of dietary treatment in patients with glycogen storage disease type IV.

Authors:  Terry G J Derks; Fabian Peeks; Foekje de Boer; Marieke Fokkert-Wilts; Hubert P J van der Doef; Marius C van den Heuvel; Edyta Szymańska; Dariusz Rokicki; Patrick T Ryan; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2020-12-21       Impact factor: 4.982

6.  Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.

Authors:  Haiqing Yi; Fengqin Gao; Stephanie Austin; Priya S Kishnani; Baodong Sun
Journal:  Mol Genet Metab Rep       Date:  2016-10-04

7.  Liver Transplantation for Hepatic Adenoma: A UNOS Database Analysis and Systematic Review of the Literature.

Authors:  Ioannis A Ziogas; Panagiotis T Tasoudis; Nikolaos Serifis; Sophoclis P Alexopoulos; Martin I Montenovo; Alexandra Shingina
Journal:  Transplant Direct       Date:  2022-01-05

8.  A Case of Glycogen Storage Disease IV with Rare Homozygous Mutations in the Glycogen Branching Enzyme Gene.

Authors:  So Yoon Choi; Ben Kang; Jae Young Choe; Yoon Lee; Hyo Jeong Jang; Hyung-Doo Park; Suk-Koo Lee; Yon Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2018-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.